A Charter to Fundamentally Change the Role of Oral Corticosteroids in the Management of Asthma.
Asthma
Long-term
Oral corticosteroids
Journal
Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
received:
08
11
2022
accepted:
21
02
2023
medline:
29
5
2023
pubmed:
8
4
2023
entrez:
7
4
2023
Statut:
ppublish
Résumé
Asthma affects 339 million people worldwide, with an estimated 5-10% experiencing severe asthma. In emergency settings, oral corticosteroids (OCS) can be lifesaving, but acute and long-term treatment can produce clinically important adverse outcomes and increase the risk of mortality. Therefore, global guidelines recommend limiting the use of OCS. Despite the risks, research indicates that 40-60% of people with severe asthma are receiving or have received long-term OCS treatment. Although often perceived as a low-cost option, long-term OCS use can result in significant health impairments and costs owing to adverse outcomes and increased utilization of healthcare resources. Alternative treatment methods, such as biologics, may produce cost-saving benefits with a better safety profile. A comprehensive and concerted effort is necessary to tackle the continued reliance on OCS. Accordingly, a threshold for OCS use should be established to help identify patients at risk of OCS-related adverse outcomes. Receiving a total dose of more than 500 mg per year should trigger a review and specialist referral. Changes to national and local policies, following examples from other chronic diseases, will be crucial to achieving this goal. Globally, multiple barriers to change still exist, but specific steps have been identified to help clinicians reduce reliance on OCS. Implementing these changes will result in positive health outcomes for patients and social and economic benefits for societies.
Identifiants
pubmed: 37027115
doi: 10.1007/s12325-023-02479-0
pii: 10.1007/s12325-023-02479-0
pmc: PMC10080509
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Biological Products
0
Anti-Asthmatic Agents
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
2577-2594Informations de copyright
© 2023. The Author(s).
Références
Global Asthma Network. The Global Asthma Report. 2018. http://globalasthmareport.org/ . Accessed 1 Nov 2022.
Enilari O, Sinha S. The global impact of asthma in adult populations. Ann Glob Health. 2019;85(1):2.
Menzies-Gow A, Canonica GW, Winders TA, Correia de Sousa J, Upham JW, Fink-Wagner AH. A charter to improve patient care in severe asthma. Adv Ther. 2018;35(10):1485–96.
pubmed: 30182174
pmcid: 6182619
doi: 10.1007/s12325-018-0777-y
Hekking PW, Wener RR, Amelink M, Zwinderman AH, Bouvy ML, Bel EH. The prevalence of severe refractory asthma. J Allergy Clin Immunol. 2015;135(4):896–902.
pubmed: 25441637
doi: 10.1016/j.jaci.2014.08.042
Shaw DE, Sousa AR, Fowler SJ, et al. Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. Eur Respir J. 2015;46(5):1308–21.
pubmed: 26357963
doi: 10.1183/13993003.00779-2015
Asthma UK. Severe asthma: the unmet need and the global challenge 2017. https://www.asthma.org.uk/1dcce9e9/globalassets/get-involved/external-affairs-campaigns/publications/severe-asthma-report/auk_severeasthma_2017.pdf . Accessed 1 Nov 2022.
Foster JM, McDonald VM, Guo M, Reddel HK. “I have lost in every facet of my life”: the hidden burden of severe asthma. Eur Respir J. 2017;50(3):1700765.
pubmed: 28931662
doi: 10.1183/13993003.00765-2017
Bleecker ER, Menzies-Gow AN, Price DB, et al. Systematic literature review of systemic corticosteroid use for asthma management. Am J Respir Crit Care Med. 2020;201(3):276–93.
pubmed: 31525297
pmcid: 6999108
doi: 10.1164/rccm.201904-0903SO
Chung LP, Upham JW, Bardin PG, Hew M. Rational oral corticosteroid use in adult severe asthma: a narrative review. Respirology. 2020;25(2):161–72.
pubmed: 31713955
doi: 10.1111/resp.13730
Tran TN, King E, Sarkar R, et al. Oral corticosteroid prescription patterns for asthma in France, Germany, Italy and the UK. Eur Respir J. 2020;55(6):1902363.
Heffler E, Blasi F, Latorre M, et al. The severe asthma network in Italy: findings and perspectives. J Allergy Clin Immunol Pract. 2019;7(5):1462–8.
pubmed: 30368004
doi: 10.1016/j.jaip.2018.10.016
Tran TN, Maclachlan S, Hicks W, et al. Oral corticosteroid treatment patterns of patients in the United States with persistent asthma. J Allergy Clin Immunol Pract. 2021;9(1):338–46.e3.
pubmed: 32569754
doi: 10.1016/j.jaip.2020.06.019
Rice JB, White AG, Scarpati LM, Wan G, Nelson WW. Long-term systemic corticosteroid exposure: a systematic literature review. Clin Ther. 2017;39(11):2216–29.
pubmed: 29055500
doi: 10.1016/j.clinthera.2017.09.011
Covvey JR, Johnston BF, Wood F, Boyter AC. Is the BTS/SIGN guideline confusing? A retrospective database analysis of asthma therapy. Prim Care Respir J. 2013;22(3):290–5.
pubmed: 23797678
pmcid: 6442817
doi: 10.4104/pcrj.2013.00060
Cataldo D, Louis R, Michils A, et al. Severe asthma: oral corticosteroid alternatives and the need for optimal referral pathways. J Asthma. 2020:58(4):448–58.
Papadopoulos NG, Barnes P, Canonica GW, et al. The evolving algorithm of biological selection in severe asthma. Allergy. 2020;75(7):1555–63.
pubmed: 32124991
doi: 10.1111/all.14256
Price DB, Trudo F, Voorham J, et al. Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study. J Asthma Allergy. 2018;11:193–204.
pubmed: 30214247
pmcid: 6121746
doi: 10.2147/JAA.S176026
Asthma and Allergy Network. Oral corticosteroid stewardship statement 2018. https://www.aafa.org/media/2244/oral-corticosteroid-stewardship-statement-november-2018.pdf . Accessed 1 Nov 2022.
Sweeney J, Patterson CC, Menzies-Gow A, et al. Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the Optimum Patient Care Research Database and the British Thoracic Difficult Asthma Registry. Thorax. 2016;71(4):339–46.
pubmed: 26819354
doi: 10.1136/thoraxjnl-2015-207630
Ekstrom M, Nwaru BI, Hasvold P, Wiklund F, Telg G, Janson C. Oral corticosteroid use, morbidity and mortality in asthma: a nationwide prospective cohort study in Sweden. Allergy. 2019;74(11):2181–90.
pubmed: 31095758
doi: 10.1111/all.13874
Lee H, Ryu J, Nam E, et al. Increased mortality in patients with corticosteroid-dependent asthma: a nationwide population-based study. Eur Respir J. 2019;54(5):1900804.
Yaghoubi M, Adibi A, Safari A, FitzGerald JM, Sadatsafavi M. The projected economic and health burden of uncontrolled asthma in the United States. Am J Respir Crit Care Med. 2019;200(9):1102–12.
pubmed: 31166782
pmcid: 6888652
doi: 10.1164/rccm.201901-0016OC
Raimundo K, Ngai KM, Chang E, Broder M, Griffin NM. Cost and healthcare utilization in asthma patients with high oral corticosteroid-use. In: American Academy of Allergy, Asthma and Immunology annual meeting; March 4–7; Los Angeles, CA2016.
Luskin A, Antonova E, Broder M, Chang E, Omachi T, Ledford D. Health care resource use and costs associated with possible side effects of high oral corticosteroid use in asthma: a claims-based analysis. Clinicoecon Outcomes Res. 2016;8:641–8.
pubmed: 27822075
pmcid: 5087584
doi: 10.2147/CEOR.S115025
Bagnasco D, Povero M, Pradelli L, et al. Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life. World Allergy Organ J. 2021;14(2):100509.
pubmed: 33598095
pmcid: 7846931
doi: 10.1016/j.waojou.2021.100509
Soong W, Chipps BE, O’Quinn S, et al. Health-related quality of life and productivity among US patients with severe asthma. J Asthma Allergy. 2021;14:713–25.
pubmed: 34211280
pmcid: 8240863
doi: 10.2147/JAA.S305513
Walters GI, Marsh J, Bahron A, Hussein H, Krishna MT, Mansur AH. Associations between employment and sociodemographic and health-related factors in asthmatic patients assessed at a regional severe asthma service. J Allergy Clin Immunol Pract. 2022;10:1646–8.
pubmed: 35259536
doi: 10.1016/j.jaip.2022.02.031
Ismaila AS, Sayani AP, Marin M, Su Z. Clinical, economic, and humanistic burden of asthma in Canada: a systematic review. BMC Pulm Med. 2013;13:70.
pubmed: 24304726
pmcid: 4235031
doi: 10.1186/1471-2466-13-70
Kohen DE. Asthma and school functioning. Health Rep. 2010;21(4):35–45.
pubmed: 21269010
O’Neill S, Sweeney J, Patterson CC, et al. The cost of treating severe refractory asthma in the UK: an economic analysis from the British Thoracic Society Difficult Asthma Registry. Thorax. 2015;70(4):376–8.
pubmed: 24917087
doi: 10.1136/thoraxjnl-2013-204114
Kerkhof M, Tran TN, Soriano JB, et al. Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population. Thorax. 2018;73(2):116–24.
pubmed: 28918400
doi: 10.1136/thoraxjnl-2017-210531
Janson C, Lisspers K, Ställberg B, et al. Health care resource utilization and cost for asthma patients regularly treated with oral corticosteroids—a Swedish observational cohort study (PACEHR). Respir Res. 2018;19(1):168.
Canonica GW, Colombo GL, Bruno GM, et al. Shadow cost of oral corticosteroids-related adverse events: a pharmacoeconomic evaluation applied to real-life data from the Severe Asthma Network in Italy (SANI) registry. World Allergy Organ J. 2019;12(1):100007.
pubmed: 30937132
pmcid: 6439414
doi: 10.1016/j.waojou.2018.12.001
Voorham J, Xu X, Price DB, et al. Healthcare resource utilization and costs associated with incremental systemic corticosteroid exposure in asthma. Allergy. 2019;74(2):273–83.
pubmed: 29987879
doi: 10.1111/all.13556
Hurst J, Jenkins C, A M-G. A blueprint for change: how changes in chronic airways disease care can support the development of a more sustainable and resilient health system. AstraZenica. 2021. https://www3.weforum.org/docs/WEF_Blueprint_for_change_Chronic_airway_disease.pdf . Accessed 1 Nov 2022.
Suruki RY, Daugherty JB, Boudiaf N, Albers FC. The frequency of asthma exacerbations and healthcare utilization in patients with asthma from the UK and USA. BMC Pulm Med. 2017;17(1):74.
The Asthma UK and British Lung Foundation Partnership. Biologic therapies for severe asthma 2020. https://www.asthma.org.uk/advice/severe-asthma/treating-severe-asthma/biologic-therapies/ . Accessed 1 Nov 2022.
Agache I, Akdis CA, Akdis M, et al. EAACI biologicals guidelines—recommendations for severe asthma. Allergy. 2021;76(1):14–44.
pubmed: 32484954
doi: 10.1111/all.14425
Doroudchi A, Pathria M, Modena BD. Asthma biologics. Ann Allergy Asthma Immunol. 2020;124(1):44–56.
pubmed: 31655122
doi: 10.1016/j.anai.2019.10.016
AstraZeneca. TEZSPIRE (tezepelumab-ekko) prescribing information. 2021. https://den8dhaj6zs0e.cloudfront.net/50fd68b9-106b-4550-b5d0-12b045f8b184/e306dc06-d580-4457-b15f-9f28545ad63a/e306dc06-d580-4457-b15f-9f28545ad63a_viewable_rendition__v.pdf . Accessed 1 Nov 2022.
Porsbjerg CM, Menzies-Gow AN, Tran TN, et al. Global variability in administrative approval prescription criteria for biologic therapy in severe asthma. J Allergy Clin Immunol Pract. 2022;10(5):1202-16.e23.
pubmed: 34990866
doi: 10.1016/j.jaip.2021.12.027
Volmer T, Effenberger T, Trautner C, Buhl R. Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature. Eur Respir J. 2018;52(4):1800703.
Quint JK, Arnetorp S, Kocks JWH, et al. Short-acting beta-2-agonist exposure and severe asthma exacerbations: SABINA findings from Europe and North America. J Allergy Clin Immunol Pract. 2022;10(9)2297–2309.e10.
Haughney J, Winders TA, Holmes S, et al. Global quality standard for identification and management of severe asthma. Adv Ther. 2020;37(9):3645–59.
pubmed: 32725419
pmcid: 7444397
doi: 10.1007/s12325-020-01450-7
Taube C, Bramlage P, Hofer A, Anderson D. Prevalence of oral corticosteroid use in the German severe asthma population. ERJ Open Res. 2019;5(4):00092–2019.
pubmed: 31687373
pmcid: 6819991
doi: 10.1183/23120541.00092-2019
Almutairi K, Nossent J, Preen D, Keen H, Inderjeeth C. The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review. Rheumatol Int. 2021;41(5):863–77.
pubmed: 33175207
doi: 10.1007/s00296-020-04731-0
Del Rincón I, Battafarano DF, Restrepo JF, Erikson JM, Escalante A. Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis. Arthritis Rheumatol. 2014;66(2):264–72.
pubmed: 24504798
doi: 10.1002/art.38210
Black RJ, Lester S, Buchbinder R, et al. Factors associated with oral glucocorticoid use in patients with rheumatoid arthritis: a drug use study from a prospective national biologics registry. Arthritis Res Ther. 2017;19(1):253.
Price D, Bjermer L, Bergin DA, Martinez R. Asthma referrals: a key component of asthma management that needs to be addressed. J Asthma Allergy. 2017;10:209–23.
pubmed: 28794645
pmcid: 5536139
doi: 10.2147/JAA.S134300
McCoul ED. Steroid shots and the culture of instant gratification. JAMA Otolaryngol Head Neck Surg. 2021;147(2):121–2.
doi: 10.1001/jamaoto.2020.3413
Global Initiative for Asthma. Global strategy for asthma management and prevention. 2021. https://ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf . Accessed 1 Nov 2022.
Canonica GW, Blasi F, Paggiaro P, et al. Oral CorticoSteroid sparing with biologics in severe asthma: a remark of the Severe Asthma Network in Italy (SANI). World Allergy Org J. 2020;13(10): 100464.
doi: 10.1016/j.waojou.2020.100464
Holmes J, Heaney LG. Measuring adherence to therapy in airways disease. Breathe. 2021;17(2):210037.
pubmed: 34295430
pmcid: 8291934
doi: 10.1183/20734735.0037-2021
Mansur AH, Hassan M, Duffy J, Webster C. Development and clinical application of a prednisolone/cortisol assay to determine adherence to maintenance oral prednisolone in severe asthma. Chest. 2020;158(3):901–12.
pubmed: 32298734
doi: 10.1016/j.chest.2020.03.056
Murphy KR, Chipps B, Beuther DA, Wise RA, McCann W, Gilbert I, et al. Development of the Asthma Impairment and Risk Questionnaire (AIRQ): a composite control measure. J Allergy Clin Immunol Pract. 2020;8(7):2263e5–74e5.
doi: 10.1016/j.jaip.2020.02.042
Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487–97.
pubmed: 16079372
doi: 10.1056/NEJMra050100
Yang JF, Chaudhuri R, Thomson NC, et al. Insights into frequent asthma exacerbations from a primary care perspective and the implications of UK National Review of Asthma Deaths recommendations. NPJ Prim Care Respir Med. 2018;28(1):35.
Ryan D, Heatley H, Heaney LG, et al. Potential severe asthma hidden in UK primary care. J Allergy Clin Immunol Pract. 2021;9(4):1612–23.e9.
pubmed: 33309935
doi: 10.1016/j.jaip.2020.11.053
Royal College of Physicians. Why asthma still kills: The National Review of Asthma Deaths (NRAD) Confidential Enquiry report. London: RCP [Internet]. 2014. https://www.rcplondon.ac.uk/projects/outputs/why-asthma-still-kills . Accessed 1 Nov 2022.
European Centre for Disease Prevention and Control. Antimicrobial resistance. 2020. https://www.ecdc.europa.eu/en/antimicrobial-resistance . Accessed 1 Nov 2022.
Boulet L-P, Godbout K. Oral corticosteroids tapering in severe asthma. Am J Respir Crit Care Med. 2021;203(7):795–6.
pubmed: 33211979
pmcid: 8017580
doi: 10.1164/rccm.202010-4001ED
Drake SM, Simpson A, Fowler SJ. Asthma diagnosis: the changing face of guidelines. Pulm Ther. 2019;5(2):103–15.
pubmed: 32026404
pmcid: 6967246
doi: 10.1007/s41030-019-0093-y
Makhinova T, Barner JC, Richards KM, Rascati KL. Asthma controller medication adherence, risk of exacerbation, and use of rescue agents among Texas Medicaid patients with persistent asthma. J Manag Care Spec Pharm. 2015;21(12):1124–32.
pubmed: 26679962
British Thoracic Society/Scottish Intercollegiate Guideline Network (BTS/SIGN). British guideline on the management of asthma. 2019. https://www.brit-thoracic.org.uk/quality-improvement/guidelines/asthma/ . Accessed 1 Nov 2022.
Song W-J, Won H-K, Lee SY, et al. Patients’ experiences of asthma exacerbation and management: a qualitative study of severe asthma. ERJ Open Res. 2021;7(2):00528–2020.
pubmed: 33834052
pmcid: 8021804
doi: 10.1183/23120541.00528-2020
Amin S, Soliman M, McIvor A, Cave A, Cabrera C. Understanding patient perspectives on medication adherence in asthma: a targeted review of qualitative studies. Patient Prefer Adherence. 2020;14:541–51.
pubmed: 32210541
pmcid: 7071882
doi: 10.2147/PPA.S234651
Nwaru BI, Ekstrom M, Hasvold P, Wiklund F, Telg G, Janson C. Overuse of short-acting beta2-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme. Eur Respir J. 2020;55(4):1901872.
pubmed: 31949111
pmcid: 7160635
doi: 10.1183/13993003.01872-2019
Reddel HK, Fitzgerald JM, Bateman ED, et al. GINA 2019: a fundamental change in asthma management. Eur Respir J. 2019;53(6):1901046.
pubmed: 31249014
doi: 10.1183/13993003.01046-2019
Kaplan A, Mitchell PD, Cave AJ, Gagnon R, Foran V, Ellis AK. Effective asthma management: is it time to let the AIR out of SABA? J Clin Med. 2020;9(4):921.
pubmed: 32230875
pmcid: 7230470
doi: 10.3390/jcm9040921
Baron AJ, Flokstra-De Blok BM, Kerstjens HA, et al. High use of SABAs is associated with higher exacerbation rate in Dutch patients with asthma. J Asthma Allergy. 2021;14:851–61.
pubmed: 34285512
pmcid: 8285233
doi: 10.2147/JAA.S292943
Allen-Ramey FC, Nelsen LM, Leader JB, Mercer D, Kirchner HL, Jones JB. Electronic health record-based assessment of oral corticosteroid use in a population of primary care patients with asthma: an observational study. Allergy Asthma Clin Immunol. 2013;9(1):27.
pubmed: 23924393
pmcid: 3846655
doi: 10.1186/1710-1492-9-27
Busse WW, Morgan WJ, Taggart V, Togias A. Asthma outcomes workshop: overview. J Allergy Clin Immunol. 2012;129(3):S1–8.
pubmed: 22386504
pmcid: 4259286
doi: 10.1016/j.jaci.2011.12.985
AstraZeneca. Astha Referral Identifier. 2023. https://www.asthmareferid.com/ . Accessed 1 Nov 2022.
Beekman M, Hales J, Al-Ahmad M, Del Olmo R, Tan TL. Breaking the vicious circle-the Asthma Referral Identifier (ReferID) tool. NPJ Prim Care Respir Med. 2022;32(1):40.
pubmed: 36209272
pmcid: 9547879
doi: 10.1038/s41533-022-00296-6
Murphy AC, Proeschal A, Brightling CE, et al. The relationship between clinical outcomes and medication adherence in difficult-to-control asthma. Thorax. 2012;67(8):751–3.
pubmed: 22436168
doi: 10.1136/thoraxjnl-2011-201096
Global Initiative for Asthma. Global strategy for asthma management and prevention. 2020. https://ginasthma.org/wp-content/uploads/2020/06/GINA-2020-report_20_06_04-1-wms.pdf . Accessed 1 Nov 2022.
Cooper V, Metcalf L, Versnel J, Upton J, Walker S, Horne R. Patient-reported side effects, concerns and adherence to corticosteroid treatment for asthma, and comparison with physician estimates of side-effect prevalence: a UK-wide, cross-sectional study. NPJ Prim Care Respir Med. 2015;25(1):15026.
pubmed: 26158805
pmcid: 4497315
doi: 10.1038/npjpcrm.2015.26
Jaffuel D, Fabry-Vendrand C, Darnal E, Wilczynski O, Pain E, Bourdin A. Perception of oral corticosteroids in adult patients with asthma in France. J Asthma. 2021;58(7):946–57.
pubmed: 32285714
doi: 10.1080/02770903.2020.1748048
NHS England. Steroid Emergency Card to support early recognition and treatment of adrenal crisis in adults. 2020 [updated March 2022]. https://www.england.nhs.uk/2020/08/steroid-emergency-card-to-support-early-recognition-and-treatment-of-adrenal-crisis-in-adults/ . Accessed 1 Nov 2022.
Kaye AD, Okeagu CN, Pham AD, et al. Economic impact of COVID-19 pandemic on healthcare facilities and systems: international perspectives. Best Pract Res Clin Anaesthesiol. 2021;35(3):293–306.
pubmed: 34511220
doi: 10.1016/j.bpa.2020.11.009
Smolen JS, Landewe RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685–99.
pubmed: 31969328
doi: 10.1136/annrheumdis-2019-216655